July 11 (Reuters) - Pfizer ( PFE ) said on Thursday it

would conduct studies in the second-half of 2024 on a reworked,

once-a-day version of its experimental obesity pill,

danuglipron.

The drugmaker last year said it was focusing on

danuglipron's development after scrapping a separate, once-daily

pill due to concerns about liver safety.

Pfizer ( PFE ) is testing both a once-daily modified release dosing

and also a twice-daily form of danuglipron.

(Reporting by Manas Mishra in Bengaluru; Editing by Shinjini

Ganguli)